ADAPTIVE BIOTECHNOLOGIES CORPORATION Operating Lease Right-of-Use Assets
ADAPTIVE BIOTECHNOLOGIES CORPORATION (ADPT) had Operating Lease Right-of-Use Assets of $39.12 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:OperatingLeaseRightOfUseAsset · last filed 2026-08-04
- 2026-06-30: Operating Lease, Right-of-Use Asset $39.12M.
- 2026-03-31: Operating Lease, Right-of-Use Asset $40.25M.
- 2025-12-31: Operating Lease, Right-of-Use Asset $40.62M.
- 2025-09-30: Operating Lease, Right-of-Use Asset $41.99M.
| Period end | Operating Lease, Right-of-Use Asset |
|---|---|
| 2026-06-30 | $39.12M 10-Q · filed 2026-08-04 |
| 2026-03-31 | $40.25M 10-Q · filed 2026-05-05 |
| 2025-12-31 | $40.62M 10-Q · filed 2026-08-04 |
| 2025-09-30 | $41.99M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $43.34M 10-Q · filed 2025-08-05 |
| 2025-03-31 | $44.00M 10-Q · filed 2025-05-01 |
| 2024-12-31 | $45.77M 10-K · filed 2026-02-26 |
| 2024-09-30 | $46.53M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $48.52M 10-Q · filed 2024-08-01 |
| 2024-03-31 | $51.00M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $52.10M 10-K · filed 2025-03-03 |
| 2023-09-30 | $75.26M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $77.11M 10-Q · filed 2023-08-02 |
| 2023-03-31 | $78.96M 10-Q · filed 2023-05-03 |
| 2022-12-31 | $80.76M 10-K · filed 2024-02-29 |
| 2022-09-30 | $82.61M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $84.40M 10-Q · filed 2022-08-03 |
| 2022-03-31 | $85.63M 10-Q · filed 2022-05-04 |
| 2021-12-31 | $87.68M 10-K · filed 2023-02-14 |
| 2021-09-30 | $89.45M 10-Q · filed 2021-11-03 |
| 2021-06-30 | $92.07M 10-Q · filed 2021-08-04 |
| 2021-03-31 | $88.50M 10-Q · filed 2021-05-05 |
| 2020-12-31 | $99.35M 10-K · filed 2022-02-15 |
| 2020-09-30 | $37.73M 10-Q · filed 2020-11-10 |
| 2020-06-30 | $37.62M 10-Q · filed 2020-08-10 |
| 2020-03-31 | $31.06M 10-Q · filed 2020-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |